Nicotinic acid and nicotinamide: A review of their use for hyperphosphatemia in dialysis patients

Pharmacotherapy

Volumn 33, Issue 6, 2013, Pages 683-690

  Rennick, Amanda ^a   Kalakeche, Rabih ^b   Seel, Lindsey ^a   Shepler, Brian ^a  

^a PURDUE UNIVERSITY   (United States)

^b IU Health Arnett Hospital   (United States)

Author keywords

Chronic kidney disease; Hemodialysis; Hyperphosphatemia; Nicotinamide; Nicotinic acid

Indexed keywords

NICOTINAMIDE; NICOTINIC ACID; PHOSPHORUS; PLACEBO;

BEDTIME DOSAGE; DIARRHEA; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INDICATION; DRUG MEGADOSE; DRUG SAFETY; DRUG SCREENING; DRUG WITHDRAWAL; HEMODIALYSIS; HEMODIALYSIS PATIENT; HOT FLUSH; HUMAN; HYPERPHOSPHATEMIA; KIDNEY FAILURE; LOW DRUG DOSE; MONOTHERAPY; NONHUMAN; PERITONEAL DIALYSIS; PHOSPHATE BLOOD LEVEL; REVIEW; SIDE EFFECT; THROMBOCYTOPENIA; URINARY EXCRETION; WEIGHT REDUCTION;

ANIMALS; HUMANS; HYPERPHOSPHATEMIA; KIDNEY FAILURE, CHRONIC; NIACIN; NIACINAMIDE; PERITONEAL DIALYSIS; PHOSPHORUS; RENAL DIALYSIS;

EID: 84879576253     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1002/phar.1258     Document Type: Review

References (30)

1. Friedman EA. Consequences and management of hyperphosphatemia in patients with renal insufficiency. Kidney Int 2005;67:S1-S7.
2. Wang AY. Cardiac valve calcification as an important predictor for all cause mortality and cardiovascular mortality in long term peritoneal dialysis patients: a prospective study. J Am Soc Nephrol 2003;14:159-168.
3. Lopes A, Tong L, Thumma J, et al. Phosphate binder use and mortality among hemodialysis patients in the Dialysis Outcomes and Practice Study (DOPPS): evaluation of possible confounding by nutritional status. Am J Kidney Dis 2012;60 (1):90-101.
4. Kuboyama N, Watanabe Y, Yamaguchi M, Sato K, Suzuki T, Akiba T. Effects of niceritrol on faecal and urinary phosphate excretion in normal rats. Nephrol Dial Transplant 1999;14: 610-614.
5. Debiec H, Lorenc R. Identification of Na+, Pi-binding protein in kidney and intestinal brush-border membranes. Biochem J 1988;255:185-191.
6. Katai K, Tanaka H, Tatsumi S, et al. Nicotinamide inhibits sodium-dependent phosphate cotransport activity in rat small intestine. Nephrol Dial Transplant 1999;14:1195-201.
7. Wu KI, Bacon RA, Al-Mahrouq HA, Kempson SA. Nicotinamide as a rapid-acting inhibitor of renal brush-border phosphate transport. Am J Physiol 1988;2:F15-F21.
8. Eto N, Miyata Y, Ohno H, Yamashita T. Nicotinamide prevents the development of hyperphosphataemia by suppressing intestinal sodium dependent phosphate transporter in rats with adenine-induced renal failure. Nephrol Dial Transplant 2005;20:1378-1384.
9. Bostom AG. Binder blinders-niacin of omission? Am J Kidney Dis 2010;55:628-630.
10. Villines T, Kim A, Gore R, Taylor AJ. Niacin: the evidence, clinical use, and future direction. Curr Atheroscler Rep 2012;14:49-59.
11. Peiper JA. Overview of niacin formulations: differences in pharmacokinetics, efficacy, and safety. Am J Health-Syst Pharm 2003;60:S9-S14.
12. Niacin. Drug Point Summary. Thompson Micromedex. Greenwood Village, CO. Available from http://thomsonhc.com. Accessed June 6, 2012.
13. Menon R, Adams M, Gonzalez M, Tolbert DS, Leu JH, Cefali EA. Plasma and urine pharmacokinetics of niacin and its metabolites from an extended-release niacin formulation. Int J Clin Pharmacol Ther 2007;45(8):448-454.
14. National Institutes of Health. Nicotinamide in Hemodialysis Patients with Hyperphosphatemia (DONATO). Available at: http://clinicaltrials.gov. Accessed May 31, 2012.
15. Takahashi Y, Tanaka A, Nakamura T, et al. Nicotinamide suppresses hyperphosphatemia in hemodialysis patients. Kidney Int 2004;65:1099-1104.
16. Sampathkumar K, Selvan M, Sooraj Y, Gowthaman S, Ajeshkumar RN. Extended release nicotinic acid - a novel agent for phosphate control. Int Urol Nephrol 2006;38:171-174.
17. Sampathkumar K, Sooraj Y, Mahaldar A. Comparative efficacy of low dose nicotinic acid and lanthanum in lowering the phosphorus levels in hemodialysis patients. Paper presented at World Conference on Nephrology 2007, Rio de Janeiro, Brazil.
18. Müller D, Mehling H, Otto B, et al. Niacin lowers serum phosphate and increases HDL cholesterol in dialysis patients. Clin J Am Soc Nephrol 2007;2:1249-1254.
19. Cheng SC, Young DO, Huang Y, Delmez JA, Coyne DW. Randomized, double-blind, placebo-controlled trial of niacinamide for reduction of phosphorus in hemodialysis patients. Clin J Am Soc Nephrol 2008;3:1131-1138.
20. Valencia CA, Cruz J. Safety and effectiveness of nicotinic acid in the management of patients with chronic renal disease and hyperlipidemia associated to hyperphosphatemia. Nefrologia 2008;28(1):61-66.
21. Young DO, Cheng SC, Delmez JA, Coyne DW. The effect of oral niacinamide on plasma phosphorus concentrations in peritoneal dialysis patients. Perit Dial Int 2009;29:562-567.
22. Shahbazian H, Mohtashami A, Ghorbani A, et al. Oral nicotinamide reduces serum phosphorus, increases HDL, and induces thrombocytopenia in hemodialysis patients: a double blind randomized clinical trial. Nefrologia 2011;31(1):58-65.
23. Palmer SC, Hayen A, Macaskill P, et al. Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis. JAMA 2011;305(11):1119-1127.
24. USRDS. Altas of CKD and ESRD 2012. United States renal data systems. USRDS Coordinating Center. Minneapolis, MN. Available from http://www.usrds.org/ atlas.aspx. Accessed Oct 17 2012.
25. KDIGO. Prevention and treatment of Chronic Kidney Disease- Mineral and Bone Disorder (CKD-MBD). Kidney Int 2009;76 (113):S50-99; doi:10.1038/ki.2009. 2192
26. Niacinamide. Drug point summary. Thompson Micromedex. Greenwood Village, CO. Available from http://thomsonhc.com. Accessed October 18, 2012.
27. Goldberg AC. Clinical trial experience with extended-release niacin (Niaspan): dose-escalation study. Am J Cardiol 1998;82:35-38.
28. MacKay D, Hathcock J, Guarneri E. Niacin: chemical forms, bioavailability, and health effects. Nutr Rev 2012;70(6):357-366.
29. Renvela. Red book online. Thomson Micromedex. Greenwood Village, CO. Available from http://thomsonhc.com. Accessed May 28, 2012.
30. Niacin. Red book online. Thompson Micromedex. Greenwood Village, CO. Available from http://thomsonhc.com. Accessed May 28, 2012.